A circulating cfDNA analysis combined with the determination of pro-platelet basic protein (PPBP) and PAD4 expression can effectively distinguish healthy donors from NSCLC patients, which may facilitate early lung cancer diagnosis or screening detection [249]. This evidence concerns the gene PPBP and lung carcinoma.